Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Post-Mkt 11-04 19:36:08 EST

79.22

-2.71

-3.31%

盘后79.22

+0.000.00%

19:30 EST

High84.98	Low71.29	Vol2.20M
Open84.98	D1 Closing81.93	Amplitude16.71%
Mkt Cap8.56B	Tradable Cap7.76B	Total Shares108.10M
T/O168.91M	T/O Rate2.24%	Tradable Shares97.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":79.22,"timestamp":1793826000000,"preClose":81.93,"halted":0,"volume":2195653,"hourTrading":{"tag":"盘后","latestPrice":79.22,"preClose":79.22,"latestTime":"19:30 EST","volume":78443,"amount":6214271.71746,"timestamp":1793838603595,"change":0,"changeRate":0,"amplitude":0.01944},"delay":0,"changeRate":-0.033077016965702526,"floatShares":97893679,"shares":108098397,"eps":0.453654,"marketStatus":"Post-Mkt","change":-2.71,"latestTime":"11-04 19:36:08 EST","open":84.98,"high":84.98,"low":71.29,"amount":168905437.4616,"amplitude":0.167094,"askPrice":79.22,"askSize":4,"bidPrice":77.68,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.453654,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1793840400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":81.93,"preHourTrading":{"tag":"盘前","latestPrice":84.46,"preClose":81.93,"latestTime":"09:29 EST","volume":3248,"amount":273234.505152,"timestamp":1793802599999,"change":2.53,"changeRate":0.03088,"amplitude":0.115953},"postHourTrading":{"tag":"盘后","latestPrice":79.22,"preClose":79.22,"latestTime":"19:30 EST","volume":78443,"amount":6214271.71746,"timestamp":1793838603595,"change":0,"changeRate":0,"amplitude":0.01944},"volumeRatio":1.619254,"impliedVol":0.9363,"impliedVolPercentile":0.9044},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2681920590","title":"Corcept Therapeutics President, Oncology Roberto Wandenkolk Vieira Reports Sale of Common Shares Worth $674,068.7958","url":"https://stock-news.laohu8.com/highlight/detail?id=2681920590","media":"Reuters","labels":["insiderTrades"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2681920590?lang=en_us&edition=fundamental","pubTime":"2026-11-05 08:21","pubTimestamp":1793838096,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics President, Oncology Roberto Wandenkolk Vieira Reports Sale of Common Shares Worth $674,068.7958Corcept Therapeutics President, Oncology, Roberto Wandenkolk Vieira sold 8,333 commo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL51pJLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Corcept Therapeutics President, Oncology Roberto Wandenkolk Vieira Reports Sale of Common Shares Worth $674,068.7958","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","LU1559883803.SGD","FBT","BK4532","LU0566484027.USD","PSCH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681069818","title":"Corcept Therapeutics Price Target Raised to $173.00/Share from $165.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2681069818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681069818?lang=en_us&edition=fundamental","pubTime":"2026-11-05 01:32","pubTimestamp":1793813520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680035992","title":"US Research Roundup-Amgen, Carmax, Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2680035992","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680035992?lang=en_us&edition=fundamental","pubTime":"2026-11-04 17:01","pubTimestamp":1793782892,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Amgen, Carmax, PfizerNov 4 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Amgen, Carmax and Pfizer, on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL3N46L0W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMHX","ADTN","UPGR","BEAM","BKNU","CWH","ADBG","AME","AMDU","CNK","CCB","ADBE","ALAB","KMX","CMCO","AMD","AN","BALL","CYH","TBXU","BMRN","BKNG","ADM","AMRX","CBLL","ALKS","APO","ANET","ATRC","CE","PBE","EGGY","AMGN","AXSM","CORT","PRVT","ASBH","BRCC","XNTK","AMWL","ARVN","XYZ","BR","APTV","BE","AESI","ADUS","CNM","SMOG","CALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680054627","title":"Corcept Therapeutics Incorporated Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2680054627","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680054627?lang=en_us&edition=fundamental","pubTime":"2026-11-04 06:43","pubTimestamp":1793745816,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Incorporated reports results for the quarter ended September 30 - Earnings SummaryCorcept Therapeutics IncorporatedCORT.OQreported quarterly adjusted earnings of $1.01 per share f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL5N46K2XA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","PSCH","BK4532","CORT","LU1559883803.SGD","FBT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680032117","title":"Corcept Therapeutics Forecasts 2026 Revenue of $1.1 Billion-$1.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2680032117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680032117?lang=en_us&edition=fundamental","pubTime":"2026-11-04 06:16","pubTimestamp":1793744201,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Forecasts 2026 Revenue of $1.1 Billion-$1.2 BillionCorcept Therapeutics forecasts 2026 revenue of $1.1 billion to $1.2 billion.Third-quarter revenue totaled $341 million, up from ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nNDL9GvCfW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","LU1559883803.SGD","BK4532","LU0566484027.USD","BK4007","FBT","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680084977","title":"GUIDANCE: (CORT) Corcept Therapeutics Reiterates 2026 Revenue Guidance of $1.1B-$1.2B, vs. FactSet Est of $1.15B","url":"https://stock-news.laohu8.com/highlight/detail?id=2680084977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680084977?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:44","pubTimestamp":1793742252,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CORT) Corcept Therapeutics Reiterates 2026 Revenue Guidance of $1.1B-$1.2B, vs. FactSet Est of $1.15B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680170811","title":"Earnings Flash (CORT) Corcept Therapeutics Posts Q3 EPS $1.01, vs. FactSet Est of $0.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2680170811","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680170811?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:42","pubTimestamp":1793742133,"startTime":"0","endTime":"0","summary":"Earnings Flash (CORT) Corcept Therapeutics Posts Q3 EPS $1.01, vs. FactSet Est of $0.79","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680770777","title":"Corcept Therapeutics Q3 Revenue Beats Estimates on Strong Lifyorli Uptake","url":"https://stock-news.laohu8.com/highlight/detail?id=2680770777","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680770777?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:16","pubTimestamp":1793740574,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Q3 revenue beats estimates on strong Lifyorli uptakeOverviewUS biopharma company's Q3 revenue rose 64% yr/yr, beating analyst expectationsQ3 net income surged to $126.8 mln from $","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL2N46K146:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","PSCH","BK4532","LU0566484027.USD","LU1559883803.SGD","FBT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680772203","title":"Corcept Therapeutics Q3 EPS USD 1.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2680772203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680772203?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:06","pubTimestamp":1793739960,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept Therapeutics Q3 EPS USD 1.01Nov 03 (Reuters) - Corcept Therapeutics Q3 revenue USD 340.472 million vs. IBES estimate USD 336.4 million.Q3 net income USD 126.778 millionoutlook FY revenue USD 1,100-1,200 million vs. IBES estimate USD 1,146 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nPLXPPKS4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","LU0566484027.USD","FBT","PSCH","CORT","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680767374","title":"Analysts Are Bullish on Top NA Stocks: Seaport Therapeutics, Inc. (SPTX), Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680767374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680767374?lang=en_us&edition=fundamental","pubTime":"2026-11-03 03:00","pubTimestamp":1793646024,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Seaport Therapeutics, Inc. (SPTX) and Corcept Therapeutics (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-seaport-therapeutics-inc-sptx-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-seaport-therapeutics-inc-sptx-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4141","SPTX","LU0566484027.USD","NA","PSCH","FBT","BK4532","LU1559883803.SGD","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678409488","title":"Corcept Therapeutics Updates Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2678409488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678409488?lang=en_us&edition=fundamental","pubTime":"2026-10-28 04:05","pubTimestamp":1793131524,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics updates financial calendarCorcept Therapeutics will report third-quarter financial results on November 3, 2026.A corporate update and conference call are scheduled for the same day at 5 p.m. Eastern Time .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire  on October 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL4VtcHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","FBT","LU0566484027.USD","CORT","PSCH","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678122488","title":"Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2678122488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678122488?lang=en_us&edition=fundamental","pubTime":"2026-10-28 04:05","pubTimestamp":1793131501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nTUA9YDSJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","LU1559883803.SGD","PSCH","LU0566484027.USD","BK4532","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678724192","title":"U.S. Stocks on the MOVE-Roper, Corcept, Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2678724192","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678724192?lang=en_us&edition=fundamental","pubTime":"2026-10-26 23:40","pubTimestamp":1793029200,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Roper, Corcept, ModernaOct 26 (Reuters)-Wall Street's main indexes edged up on Monday, led by advances in technology shares, while investors assessed Anthropic's IPO filin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nL6N46C0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU0823417653.USD","LU0823417737.USD","BK4139","LU0056508442.USD","LU2506952097.USD","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","LGHT","LU0511384066.AUD","LU1585245621.USD","PSCH","BK4548","LU2360106780.USD","LU2506952170.USD","WDNA","LU2250418816.HKD","MRNY","LU0289961442.SGD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","CORT","LU0256331488.USD","ROP","BK4533","LU0566484027.USD","LU1623119135.USD","IE00B64QTZ34.USD","LU1712237335.SGD","LU1852331112.SGD","LU0069063385.USD","MRNX","IE00BN0W2T93.GBP","FBT","GNOM","LU2506951875.HKD","BK4551","BK4007","LU0342679015.USD","IE00BN0W2V16.EUR","LU0472753341.HKD","RRC","LU1633808545.USD","LU2506951958.HKD","BK4206","BK4608","BK4501","FICO","LU1430594728.SGD","LU0353189680.USD","LU0353189763.USD","BK4534","BK4568","BK4585","LU0057025933.USD","BK4588","BK4532","IE0008368304.USD","BK4023","MRNA","LU2087625088.SGD","BK4213","LU1559883803.SGD","IE00BLDYK493.USD","IDNA","FDIQ","LU0950375773.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678196440","title":"Corcept Therapeutics Says Trial of Lifyorli Combination Slows Ovarian Cancer Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2678196440","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678196440?lang=en_us&edition=fundamental","pubTime":"2026-10-26 21:19","pubTimestamp":1793020758,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics  said Monday that results from a mid-stage trial evaluating the combination of Lifyorli with nab-paclitaxel and bevacizumab showed the treatment slowed ovarian cancer progression and shrank tumors in patients.The pharmaceutical company said the study demonstrated a median progression-free survival of 7.2 months and an objective response rate of 59% in 95 patients with platinum-resistant ovarian cancer.Patients whose tumors return or resume growing less than six months after receiving platinum-containing therapy are deemed \"platinum-resistant,\" Corcept said.Shares of Corcept were up 2.5% in recent Thursday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1559883803.SGD","CORT","PSCH","BK4007","LU0566484027.USD","BK4532","FBT","PLTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678193382","title":"Corcept Rises After Ovarian Cancer Drug Shows Positive Results in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2678193382","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678193382?lang=en_us&edition=fundamental","pubTime":"2026-10-26 20:18","pubTimestamp":1793017101,"startTime":"0","endTime":"0","summary":"BUZZ-Corcept rises after ovarian cancer drug shows positive results in mid-stage study** Corcept TherapeuticsCORT.Oshares gain 3% to $87.23 premarket** Biotech says its ovarian cancer drug Lifyorli, c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nL3N46C0WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","BK4532","LU1559883803.SGD","FBT","CORT","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678198428","title":"Corcept Shares Rise 3% Premarket After Positive Results from Ovarian Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678198428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678198428?lang=en_us&edition=fundamental","pubTime":"2026-10-26 20:09","pubTimestamp":1793016568,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nFWN46C0YP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PSCH","LU1559883803.SGD","BK4532","LU0566484027.USD","FBT","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678522198","title":"Corcept Therapeutics Incorporated - no New Safety Signals Identified in Bella Trial for Lifyorli Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2678522198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678522198?lang=en_us&edition=fundamental","pubTime":"2026-10-26 20:00","pubTimestamp":1793016002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUA3CTSZB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","BK4007","LU1559883803.SGD","BK4532","LU0566484027.USD","FBT","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678198664","title":"Corcept Therapeutics Incorporated - Median Pfs of 7.2 Months for Lifyorli Plus Nab-Paclitaxel and Bevacizumab in Bella","url":"https://stock-news.laohu8.com/highlight/detail?id=2678198664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678198664?lang=en_us&edition=fundamental","pubTime":"2026-10-26 20:00","pubTimestamp":1793016002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUA3CTSZB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","CORT","BK4007","PSCH","LU1559883803.SGD","FBT","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678198570","title":"Corcept Reports Positive Results from Phase 2 Bella Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2678198570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678198570?lang=en_us&edition=fundamental","pubTime":"2026-10-26 20:00","pubTimestamp":1793016002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUA3CTSZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","LU0566484027.USD","FBT","CORT","LU1559883803.SGD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678198509","title":"Corcept Therapeutics Incorporated - 88% of Patients Alive at 6-Month Os Timepoint in Bella Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678198509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678198509?lang=en_us&edition=fundamental","pubTime":"2026-10-26 20:00","pubTimestamp":1793016002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUA3CTSZB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","LU0566484027.USD","FBT","CORT","LU1559883803.SGD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":-0.0646},{"period":"1month","weight":-0.2951},{"period":"3month","weight":-0.2598},{"period":"6month","weight":0.6049},{"period":"1year","weight":0.1046},{"period":"ytd","weight":1.3543}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.028192},{"month":6,"riseRate":0.478261,"avgChangeRate":0.048323},{"month":7,"riseRate":0.478261,"avgChangeRate":0.007526},{"month":8,"riseRate":0.391304,"avgChangeRate":-0.006443},{"month":9,"riseRate":0.478261,"avgChangeRate":0.060193},{"month":10,"riseRate":0.478261,"avgChangeRate":-0.018408},{"month":11,"riseRate":0.521739,"avgChangeRate":0.018449},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}